Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
The OLZ- + ZnSO 4 -treated groups (G3 and G4) were orally treated with OLZ as in G2 and ZnSO 4 at doses of 50 and 100 mg/kg, respectively for 8 weeks as proposed by Ebaid et al
Structural disruption of the primary cilium impairs these signaling processes and is associated with exacerbation of neurodegenerative pathology [261, 262]
ENHANCED SHREDDING
Sci Transl Med 9:eaan0972
10.1016/j.diabet.2020.101216 72 LanganR
DR10627-family, XGLP/GCG/GIP-32 (Guangxi Medical University / Jiangsu Normal University), TRA24 (Henan University of Technology / Chia Tai Tianqing / Shanghai Duomirui), PB-2309 (PegBio), PN-477 (Protagonist Therapeutics), CS-14 and CS-120070 (Cascade Pharmaceuticals, peptide and small-molecule respectively), FD1016 (Suzhou Yihe), UTG-4 (Guangzhou University of Chinese Medicine), XFL6 (Xi'an Jiaotong First Affiliated Hospital), RAY-0221 (Raynovent, small molecule) - a long tail of Chinese preclinical programs, predominantly peptide-format, mostly targeting obesity with secondary positioning in type 2 diabetes and MASH
US$ 25.80
US$ 28.68
US$ 21.94
US$ 20.74
